Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 13, 2023 20:30 ET | Source: ArriVent Biopharma

InnoCare and ArriVent Announce Clinical Development Collaboration

BEIJING and NEWTOWN SQUARE, Pa., July 13, 2023 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune...
March 27, 2023 07:00 ET | Source: ArriVent Biopharma

ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing

Funding from new and existing investors will support pivotal Phase 3 and additional studies of lead product candidate, furmonertinib, as well as future pipeline expansion Jim Healy, Managing Partner...
July 05, 2022 07:00 ET | Source: ArriVent Biopharma

ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations

Furmonertinib granted Fast Track Designation in this indication by the U.S. Food and Drug Administration NEWTOWN SQUARE, Pa., July 05, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., dedicated...
February 15, 2022 07:00 ET | Source: ArriVent Biopharma

ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors

NEWTOWN SQUARE, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ArriVent Biopharma, Inc., industry leaders dedicated to accelerating the global development of innovative biopharmaceutical products, today...
June 30, 2021 07:00 ET | Source: ArriVent Biopharma

ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset

Funds will be used to build ArriVent’s portfolio of innovative in-licensed assets for global development Company enters first licensing agreement with Allist Pharma, granting ArriVent ex-China...